[Targeted therapy for solid tumors in the elderly]

Area of Science:

• Oncology
• Geriatric Medicine
• Pharmacology

Background:

• Cancer incidence and mortality disproportionately affect the elderly population.
• Elderly cancer patients present unique challenges due to heterogeneity in health status, comorbidities, and polypharmacy.
• Clinical trials have historically underrepresented elderly individuals, limiting data on treatment efficacy and safety in this demographic.

Purpose of the Study:

• To review existing evidence on the effectiveness of targeted cancer therapies in elderly patients with solid tumors.
• To evaluate the specific toxicities associated with targeted therapies in the geriatric oncology population.
• To provide insights into the risk-benefit profile of targeted treatments for older adults with cancer.

Main Methods:

• Systematic review of published literature on targeted therapy for solid tumors in elderly patients.
• Analysis of clinical trial data and real-world evidence focusing on efficacy endpoints (e.g., response rates, survival).
• Assessment of reported adverse events, including specific toxicities like arterial thromboembolism and cardiotoxicity.

Main Results:

• Targeted therapies offer potential benefits over traditional chemotherapy for certain solid tumors in the elderly.
• While generally considered less toxic than chemotherapy, specific adverse events such as arterial thromboembolism (e.g., bevacizumab) and cardiotoxicity (e.g., trastuzumab) are concerns in older patients.
• Evidence suggests variability in response and toxicity based on individual patient factors and tumor type.

Conclusions:

• Targeted therapy is a viable option for elderly cancer patients, but requires careful patient selection and vigilant monitoring for known toxicities.
• Further research and dedicated clinical trials are needed to optimize the use of targeted agents in geriatric oncology.
• Personalized treatment approaches considering geriatric assessments are crucial for maximizing benefits and minimizing risks in elderly cancer patients.